Endocrine disorders during the first year after autologous stem-cell transplant

Tauchmanovà, Libuse; Selleri, Carmine; Rosa, Gennaro De; Esposito, M.; Somma, Carolina Di; Orio, Francesco; Palomba, Stefano; Lombardi, Gaetano; Rotoli, Bruno; Colao, Annamaria

doi:10.1016/j.amjmed.2005.02.009

Cited by 42 publications

(34 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Proinflammatory cytokines are able to alter Ds activity, thus leading to a decreased local T 3 production and reduced rT 3 degradation, a biochemical condition leading to local hypothyroidism (Papanicolau 2000). Proinflammatory cytokines also inhibit TRb1 gene expression (Tauchmanovà et al 2005, Kwakkel et al 2007. A reduced T 3 production by D2 inhibition or due to a dysregulation of TR expression triggered by interleukin 1b and TNFa has been described in the hypothalamus (Boelen et al 2004), hepatic cells (Boelen et al 2006, Kwakkel et al 2007) and pituitary cells (Baur et al 2000).…”

Section: Th and Cns Remyelinationmentioning

confidence: 99%

Cellular approaches to central nervous system remyelination stimulation: thyroid hormone to promote myelin repair via endogenous stem and precursor cells

Calzà¹,

Fernández²,

Giardino³

2009

Journal of Molecular Endocrinology

View full text Add to dashboard Cite

Brain and spinal cord repair is a very difficult task in view of the extremely limited repair capability of the mature central nervous system (CNS). Thus, cellular therapies are regarded as a new frontier for both acute and chronic neurological diseases characterized by neuron or oligodendroglia degeneration. Although cell replacement has been considered as the primary goal of such approaches, in recent years greater attention has been devoted to the possibility that new undifferentiated cells in damaged nervous tissue might also act in autocrine-paracrine fashion, regulating the microenvironment through the release of growth factor and cytokines, also regulating immune response and local inflammation. In this review, repair of demyelinating disease using endogenous cells will be discussed in view of the critical role played by thyroid hormones (THs) during developmental myelination, focusing on the following points: 1) endogenous stem and precursor cells during demyelinating diseases; 2) TH homeostasis in the CNS; 3) cellular and molecular mechanism regulated by TH during developmental myelination and 4) a working hypothesis to develop a rationale for the use of THs to improve remyelination through endogenous stem and precursor cells in the course of demyelinating diseases.

show abstract

Section: Th and Cns Remyelinationmentioning

confidence: 99%

Cellular approaches to central nervous system remyelination stimulation: thyroid hormone to promote myelin repair via endogenous stem and precursor cells

Calzà¹,

Fernández²,

Giardino³

2009

Journal of Molecular Endocrinology

View full text Add to dashboard Cite

show abstract

“…Existing hypothyroidism may have contributed to the alopecia in patient A5 in our series. However, endocrine dysfunction have been reported at higher incidence after SCT than permanent alopecia; 16,17 and therefore, unlikely to be the cause of significant alopecia similar to that described in our cases. Furthermore, alopecia as one of the late effects in children after HSCT is more likely to be blamed on Bu exposure than the frequent hormonal deficiencies in such patient population.…”

Section: Discussionmentioning

confidence: 40%

Six cases of permanent alopecia after various conditioning regimens commonly used in hematopoietic stem cell transplantation

Machado

Moreb

Khan

2007

Bone Marrow Transplant

View full text Add to dashboard Cite

Alopecia, a side effect of chemotherapy, is usually temporary and reversible. Irreversible alopecia has been reported after high-dose chemotherapy (HDC) and hematopoietic stem cell transplantation (HSCT) especially related to BuCy containing conditioning regimens; however, the overall incidence is not known. We conducted a retrospective study to identify patients with chemotherapy-induced permanent alopecia after HSCT. We describe six such patients, two males and four females, among 760 patients transplanted between 1997 and 2004. Median age was 45 years (range, 37-65). There were three Caucasians and three African-Americans. Median follow-up was 30 months. Conditioning regimens included BuCy, Bu/Cy and etoposide (VP16) (one of these patients received second autograft after Cy and TBI) and CyVP16 and TBI. Our data show that permanent alopecia is a significant long-term side effect of HSCT and can be seen across the spectrum of diseases and transplant types and with non-busulfan containing regimens. We have observed that patients usually accept permanent alopecia as the price for the cure and therefore true incidence of permanent alopecia may be underestimated. Our findings may also have medico legal and psychosocial implications that need to be taken into consideration when consenting patients for HSCT.

show abstract

“…All patients with subclinical hyperthyroidism had disappeared within 6 months. In addition, a mild increase in thyroid autoantibodies, which is the biochemical evidence for chronic autoimmune thyroiditis, was found in 11 patients (12%) at 3 months and in 16 patients (17%) at 12 months [8]. Because of the high incidence of antibodies autoreactive to the thyroid gland, immune-mediated thyroid destruction is hypothesized.…”

Section: Discussionmentioning

confidence: 93%

Hyperthyroidism as a latent complication of autologous hematopoietic stem cell transplantation

Feng

Lin

et al. 2008

Int J Hematol

View full text Add to dashboard Cite

Thyroid dysfunction after hematopoietic stem cell transplantation has been investigated in many studies. Most post-transplant thyroid disorders such as hypothyroidism are recognized as a late complication whilst hyperthyroidism is infrequent and transient, and usually happens early at the onset after transplant. Here, we report two rare hyperthyroid cases, developing more than 2 years after autologous stem cell transplant. We suggest that hyperthyroidism be alerted in the post-transplant care, and special attention be paid to any latent events.

show abstract

Endocrine disorders during the first year after autologous stem-cell transplant

Cited by 42 publications

References 34 publications

Cellular approaches to central nervous system remyelination stimulation: thyroid hormone to promote myelin repair via endogenous stem and precursor cells

Cellular approaches to central nervous system remyelination stimulation: thyroid hormone to promote myelin repair via endogenous stem and precursor cells

Six cases of permanent alopecia after various conditioning regimens commonly used in hematopoietic stem cell transplantation

Hyperthyroidism as a latent complication of autologous hematopoietic stem cell transplantation

Contact Info

Product

Resources

About